Cart
sales@molnova.com
AT-7519
CAS No. 844442-38-2
AT-7519 ( AT 7519;AT7519 )
Catalog No. M16135 CAS No. 844442-38-2
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 47 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 102 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | 203 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAT-7519
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
-
DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM); has antiproliferative activity against HCT116 cells with IC50 of 82 nM; exhibits good profile against cytochrome P450 isoforms (<30% inhibition at 10 uM for 1A2, 2D6, 3A4, 2C9, 2C19).Blood Cancer Phase 2 Clinical
-
SynonymsAT 7519;AT7519
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2/CyclinA;CDK4/CyclinD1;CDK5/p35;CDK9/CyclinT;GSK-3β
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number844442-38-2
-
Formula Weight382.24
-
Molecular FormulaC16H17Cl2N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESc1cc(c(c(c1)Cl)C(=O)Nc2c[nH]nc2C(=O)NC3CCNCC3)Cl
-
Chemical Name1H-Pyrazole-3-carboxamide, 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wyatt PG, et al. J Med Chem. 2008 Aug 28;51(16):4986-99.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
molnova catalog
related products
-
CDK9-IN-1
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
-
CDK9-IN-2
CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
-
YKL-5-124
YKL-5-124 is a novel potent, selective, and covalent CDK7 inhibitor (IC50=53.5 nM), inhibits CDK7/CycH/MAT1 enzymatic activity with IC50 of 9.7 nM.
